Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.
- 7-year $35M contract with extension option to 10 years
- Implementation starts immediately targeting June 2027 go-live
- Modular platform includes first UK virtual care deployment
- FY26 revenue guidance includes $8.5M from this contract
- Potential contract value rises to $49M with expansions
Major UK EPR Win Boosts Alcidion’s Growth Trajectory
Alcidion Group Limited (ASX:ALC) has clinched a substantial new contract with University Hospitals Sussex NHS Foundation Trust (UHSussex) to roll out its Miya Precision Electronic Patient Record (EPR) platform. Valued at approximately $35 million over seven years, with an option to extend to 10 years and push the total contract value (TCV) to $49 million, this deal underscores Alcidion’s growing footprint in the UK healthcare IT sector.
The contract represents Alcidion’s third EPR platform win in the UK, following a competitive tender process. The modular Miya Precision system will integrate real-time patient data access with streamlined clinical workflows, aiming to enhance patient care and operational efficiency across UHSussex’s seven hospitals serving around one million people. Notably, this deployment includes the first UK rollout of Alcidion’s virtual care module, designed to support remote patient monitoring and reduce hospital admissions.
Implementation is set to commence immediately, with an 18-month timeline targeting a phased go-live in June 2027. Alcidion expects to recognise $8.5 million in revenue in FY26 from this contract, primarily from an upfront license fee. However, the company will incur an upfront third-party cost of approximately $2 million related to the medications management module. This upfront investment reflects the broad scope and ambition of the platform’s deployment.
Strategic Importance for Alcidion and UHSussex
University Hospitals Sussex is one of the UK’s largest acute trusts, with nearly 20,000 staff and over 1.5 million outpatient appointments, emergency visits, and surgeries annually. The Trust’s digital transformation strategy aims to replace analogue systems with a unified, integrated EPR platform that supports clinical decision-making and regional healthcare integration.
Alcidion’s Managing Director Kate Quirke highlighted the progressive rollout enabled by the modular design of Miya Precision, which builds on the existing Patientrack module already live at the Trust. This approach is intended to maximise return on investment for clinicians and patients alike. The contract also includes options to expand into additional modules such as Miya Emergency and Patient Administration System (PAS), which could further increase the TCV.
UHSussex’s Chief Strategy Officer Roxanne Smith emphasised the collaborative nature of the project, noting that over a thousand staff have contributed to shaping the programme. The EPR is seen as a cornerstone for delivering consistent, high-quality care across the Trust’s hospitals and community services, aligning with their ‘Excellent Care Everywhere’ strategy.
Alcidion’s UK Expansion Builds on Recent Momentum
This contract signing follows a series of positive developments for Alcidion, including recent acquisitions and contract expansions that have bolstered its revenue and market position. The company has been steadily growing its presence in the UK and Australia, servicing over 400 hospitals and 87 healthcare organisations worldwide. Earlier this month, Alcidion reported strong cashflow and new sales momentum, remaining on track for this significant UK EPR deal to close in May 2026, consistent with prior guidance.
Moreover, the deal complements Alcidion’s broader strategy of deploying modular, AI-enabled healthcare IT solutions that improve clinical workflows and patient outcomes. The inclusion of virtual care capabilities in this contract represents a notable first for the company in the UK market, potentially opening new avenues for remote healthcare delivery.
Despite the promising outlook, the upfront third-party cost and the complexity of an 18-month implementation suggest that execution risks and timing will be key factors to watch as the project progresses.
Alcidion’s recent acquisition of Kyra flow products in Australia, which added new customers and recurring revenue streams, illustrates the company’s multi-market growth approach and diversification beyond EPR systems.
Investors will be interested in how Alcidion manages the rollout and whether additional modules are activated to realise the full potential of the contract’s $49 million ceiling. The phased deployment and modular platform design offer flexibility but also require sustained collaboration with the Trust to deliver on promised benefits.
Bottom Line?
Alcidion’s $35 million UK EPR contract signals solid growth but hinges on smooth, multi-year implementation and module expansion.
Questions in the middle?
- How will Alcidion manage the upfront third-party costs impacting near-term margins?
- What is the likelihood and timing of additional module activations pushing the TCV toward $49 million?
- Can the virtual care module deployment pave the way for further UK market expansion?